Moreover, we have found that DPP-4 inhibitor alogliptin treatment blocks the AGEs-RAGE axis and resultantly reduces albuminuria in type 2 diabetes patients [150]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.